OPKO Health (NASDAQ:OPK) vs. Ekso Bionics (NASDAQ:EKSO) Financial Survey

OPKO Health (NASDAQ:OPK) and Ekso Bionics (NASDAQ:EKSO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk.

Analyst Recommendations

This is a breakdown of current recommendations for OPKO Health and Ekso Bionics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OPKO Health	1	2	2	1	2.50
Ekso Bionics	1	0	2	0	2.33

OPKO Health currently has a consensus price target of $2.63, suggesting a potential upside of 72.70%. Ekso Bionics has a consensus price target of $562.50, suggesting a potential upside of 11,450.31%. Given Ekso Bionics’ higher probable upside, analysts clearly believe Ekso Bionics is more favorable than OPKO Health.

Institutional & Insider Ownership

64.6% of OPKO Health shares are held by institutional investors. Comparatively, 6.4% of Ekso Bionics shares are held by institutional investors. 49.7% of OPKO Health shares are held by company insiders. Comparatively, 6.0% of Ekso Bionics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares OPKO Health and Ekso Bionics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
OPKO Health	-26.68%	-13.17%	-8.28%
Ekso Bionics	-75.66%	-86.60%	-41.70%

Volatility & Risk

OPKO Health has a beta of 1.5, indicating that its share price is 50% more volatile than the S&P 500. Comparatively, Ekso Bionics has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500.

Valuation and Earnings

This table compares OPKO Health and Ekso Bionics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OPKO Health	$713.10 million	1.69	-$53.22 million	($0.25)	-6.08
Ekso Bionics	$17.92 million	0.71	-$11.33 million	($6.64)	-0.73

Ekso Bionics has lower revenue, but higher earnings than OPKO Health. OPKO Health is trading at a lower price-to-earnings ratio than Ekso Bionics, indicating that it is currently the more affordable of the two stocks.

Summary

OPKO Health beats Ekso Bionics on 11 of the 14 factors compared between the two stocks.

About OPKO Health

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.

About Ekso Bionics

Ekso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. The company provides EksoNR, a wearable bionic suit and rehabilitation device that assists physical therapists and physicians to treat patients with acquired brain injury, stroke, and spinal cord injury; Ekso Indego Therapy, an adjustable and lower-limb powered exoskeleton; Ekso Indego Personal, a powered lower limb orthosis; Ekso Nomad, a power knee ankle foot orthosis; and Ekso EV, a wearable upper body exoskeleton that elevates and supports a worker's arms to assist with tasks from chest height to overhead. Ekso Bionics Holdings, Inc. was founded in 2005 and is headquartered in San Rafael, California.